Table 1.
Comparison of characteristics of responders and non-responders at baseline and after 3 monthly administrations of anti-vascular endothelial growth factor (VEGF) therapy.
| Testing set | Validation set | |||||
|---|---|---|---|---|---|---|
| Responder | Non-responder | p-value | Responder | Non-responder | p-value | |
| Eyes, n | 29 | 21 | — | 25 | 25 | — |
| Age, years, mean (CI) | 73.3 (69.8–76.8) | 73.7 (69.2–78.2) | 0.89 | 72.2 (68.6–75.8) | 70.7 (67.3–74.1) | 0.54 |
| Sex, male, n, (%) | 15 (51.7) | 13 (61.9) | 0.48 | 16 (64.0) | 13 (52.0) | 0.4 |
| Systemic conditions at baseline | ||||||
| IHD, n, (%) | 3 (10.3) | 0 (0.0) | 0.13 | 2 (8.0) | 3 (12.0) | 0.65 |
| Stroke, n, (%) | 4 (13.8) | 3 (14.3) | 0.96 | 1 (4.0) | 0 (0) | 0.32 |
| Diabetes, n, (%) | 11 (37.9) | 3 (14.3) | 0.07 | 9 (36.0) | 6 (24.0) | 0.36 |
| Hyperlipidaemia, n, (%) | 18 (62.1) | 13 (61.9) | 0.99 | 18 (72.0) | 15 (60.0) | 0.38 |
| Hypertension, n, (%) | 20 (68.9) | 13 (61.9) | 0.61 | 15 (60.0) | 20 (80.0) | 0.13 |
| Smoking, n, (%) | 3 (10.3) | 4 (19.0) | 0.39 | 6 (24.0) | 7 (28.0) | 0.75 |
| Chronic kidney disease, n (%) | 0 (0) | 0 (0) | — | 0 (0) | 0 (0) | — |
| Clinical characteristics | ||||||
| VA at baseline, logMAR units, (CI) | 0.89 (0.68–1.10) | 0.88 (0.64–1.12) | 0.94 | 0.89 (0.66–1.12) | 0.63 (0.48–0.78) | 0.07 |
| VA at month 3, logMAR units, (CI) | 0.60 (0.43–0.77) | 0.71 (0.50–0.92) | 0.32 | 0.55 (0.41–0.82) | 0.65 (0.45–0.88) | 0.71 |
| VA at month 12, logMAR units, (CI) | 0.50 (0.28–0.74) | 0.68 (0.38–0.85) | 0.51 | 0.52 (0.31–0.78) | 0.63 (0.31–0.82) | 0.52 |
| VA change from baseline to month 3, logMAR units, (CI) | −0.26 (−0.37–−0.08) | −0.15 (−0.31–0.02) | 0.31 | −0.28 (−0.35 – −0.10) | −0.05 (−0.25–0.01) | 0.69 |
| VA change from baseline to month 12, logMAR units, (CI) | −0.38 (−0.45 – −0.12) | −0.14 (−0.30 − 0.02) | 0.58 | −0.30 (−0.35 – −0.09) | −0.03 (−0.23–0.01) | 0.53 |
| CRT at baseline, μm, (CI) | 488 (407–569) | 488 (402–574) | 0.99 | 426 (367–485) | 476 (427–525) | 0.21 |
| CRT at month 3, μm, (CI) | 291 (252–330) | 515 (399–631) | <0.01 | 275 (257–293) | 364 (321–407) | <0.01 |
| Lesion type, PCV, n (%) | 16 (55.0) | 10 (47.6) | 0.12 | 12 (48.0) | 13 (52.0) | 0.82 |
| Anti VEGF agent type | ||||||
| Bevacizumab, n, (%) | 21 (72.4) | 20 (95.2) | 0.07 | 25 | 25 | — |
| Ranibizumab, n. (%) | 1 (3.4) | — | — | — | — | — |
| Aflibercept, n, (%) | 7 (24.1) | 1 (4.8) | 0.11 | — | — | — |
Abbreviations: IHD, Ischemic heart disease; VA, visual acuity; logMAR, logarithmic of the minimum angle of resolution; CI, confidence interval; CRT, central retinal thickness.